Clinical Trials

MyeloidOther hematologic neoplasm

181 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms

NCT07424833 2026-02-20

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

Phase 1 Not yet recruiting

180 enrolled

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT05005442 2026-02-19

A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)

Phase 2 Completed

192 enrolled 22 charts

Hematologic Neoplasms

NCT06870487 2026-02-19

A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers

DermatologicHead & NeckLymphoidOther hematologic neoplasmThoracic

6 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Hodgkin Disease, Lung Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Skin Neoplasms, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT07036133 2026-02-11

SPI-FOL-102

24 enrolled

Hematologic Neoplasms

NCT07195916 2026-02-10

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

DermatologicGenitourinaryLymphoidOther hematologic neoplasm

280 enrolled

Carcinoma, Renal Cell, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT06756451 2026-01-30

This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile.

71 enrolled

Neoplasms, Hematologic Neoplasms

NCT04243499 2026-01-27

EVICTION

292 enrolled

Hematologic Neoplasms

NCT05753501 2026-01-27

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

340 enrolled

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT06359002 2026-01-20

Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.

16 enrolled

Recurrence, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT06685848 2026-01-07

Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion

Phase NA Recruiting

24 enrolled

Phase EARLY_PHASE1 Recruiting

Hypoxia, Hematologic Neoplasms

NCT07131254 2025-12-30

A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in Adult Participants With Relapsed/Refractory CD19-positive B-cell Malignant Hematological Tumors

34 enrolled

Phase 1 Not yet recruiting

Hematologic Neoplasms

NCT07294300 2025-12-19

A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological Malignancies

124 enrolled

Hematologic Neoplasms

NCT04068597 2025-12-18

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

LymphoidOther hematologic neoplasmPlasma cell

250 enrolled

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT06697184 2025-12-17

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

56 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms

NCT06465433 2025-12-10

Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab

Phase 2 Recruiting

25 enrolled

Hematologic Neoplasms

NCT06645886 2025-12-10

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies

122 enrolled

Hematologic Neoplasms

NCT06001788 2025-12-03

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

171 enrolled

Phase NA Not yet recruiting

Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT06225050 2025-12-03

HAPLO2022

18 enrolled

Phase 1 Not yet recruiting

Hematologic Neoplasms

NCT07255898 2025-12-01

A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies

33 enrolled

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT06018506 2025-11-21

A Phase I Study of BR108 in Hematological Malignancies

Phase 1 Terminated

8 enrolled

Hematologic Neoplasms

NCT06378138 2025-11-21

ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)

Phase 2/3 Recruiting

226 enrolled

Hematologic Neoplasms

NCT04067336 2025-11-10

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

263 enrolled 1 FDA

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03320642 2025-10-21

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Phase 1 Terminated

84 enrolled

Anemia, Refractory, with Excess of Blasts, Graft vs Host Disease, Hodgkin Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT02680795 2025-10-20

Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

Phase 1 Completed

17 enrolled

Hematologic Neoplasms

NCT06066203 2025-10-01

A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies

40 enrolled

Lymphoma, Non-Hodgkin, Hematologic Neoplasms

NCT06387082 2025-09-29

A Clinical Study of HMPL-506 in Patients With Hematological Malignancies

132 enrolled

Hematologic Neoplasms

NCT05104775 2025-09-26

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy

33 enrolled

Recurrence, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT05944978 2025-09-26

A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies

3 enrolled

Phase 1/2 Not yet recruiting

Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms

NCT07107204 2025-09-17

A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies

116 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Recurrence, Hematologic Neoplasms

NCT06948981 2025-09-16

GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies

46 enrolled

Hematologic Neoplasms

NCT03162536 2025-09-08

ARQ 531-101

LymphoidOther hematologic neoplasmPlasma cellSarcoma

190 enrolled

Blood Protein Disorders, Cardiovascular Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Recurrence, Vascular Diseases, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Hemostatic Disorders, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell, Dendritic Cell Sarcoma, Interdigitating

NCT05728658 2025-09-08

The Study of ICP-248 in Patients With Mature B-cell Malignancies

191 enrolled

Hematologic Neoplasms

NCT05347225 2025-08-15

MK-1026-005

12 enrolled

Hematologic Neoplasms

NCT05391022 2025-07-28

Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies

Phase 1 Completed

35 enrolled

Phase 2 Active not recruiting

Hematologic Neoplasms

NCT01594723 2025-07-23

A Study of LY2784544 in Participants With Myeloproliferative Neoplasms

110 enrolled

Hematologic Neoplasms

NCT05599932 2025-07-09

Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment

Phase 1 Completed

38 enrolled

Hematologic Neoplasms

NCT04260698 2025-07-02

Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies

Phase 3 Completed

36 enrolled

Hematologic Neoplasms

NCT06401356 2025-06-22

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

Phase 3 Recruiting

50 enrolled

Hematologic Neoplasms

NCT02074839 2025-06-08

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation